Environmental Biotechnology

Environmental Biotechnology is the branch of biotechnology that addresses environmental problems like the removal of pollution, renewable energy generation or biomass production, by use of biological processes. Environmental Biotechnology used to detect, prevent and remediate the emission of pollutants into the environment in a number of ways. Environmental biotechnology includes the use of microorganisms and their processes for the clean-up of environmental contamination, specific examples of which include ground-water treatment, treatment of leachates, and clean-up of contaminated soils, sludges and sediments.

  • Biomarkers
  • Biosensor
  • Biofuels
  • Molecular Ecology
  • Biotransformation
  • Phytoremediation
  • Mycoremediation
  • Textiles


Comments

Post a Comment

Popular posts from this blog

Medical Biotechnology

Image
Medical biotechnology   is a branch of medicine that uses living cells and cell materials to research and then produce pharmaceutical and diagnosing products. These products help treat and prevent diseases. The main aim of medical biotechnology is the Prevention, Diagnosis and Treatment of diseases. Medical Biotechnology principles are applied in   pharmacology , gene therapy, stem cells and tissue engineering. It is a rapidly evolving field integrating knowledge obtained in molecular, cell biological, genetic and immunological scientific areas. The medical biotechnology field has helped bring to market microbial pesticides, insect-resistant crops, and environmental clean-up techniques. This discovery was the result of research studies related to deoxyribonucleic acid. Many scientists in the medical   biotechnology   field study genetic engineering which involves isolating, identifying and sequencing the human genes to determine their functions. Advancements- CRISPR Tissue Nanotransfec
Read more

Beyond vaccines: emerging technologies capable of unlocking the promise of biologically targeted mRNA therapeutics

Image
Immunization requires minimal protein expression levels, while mRNA therapeutics requires a 1,000-fold-higher protein level to reach a therapeutic threshold. Efficient delivery to solid organs remains challenging. Even the tissue bioavailability, circulatory half-life, and efficiency of the LNP-based carrier could be rate-limiting when it is delivered to the target tissue. Even with optimized mRNA chemical modifications and advanced LNPs, chronic dosing eventually activates innate immunity, parallelly attenuating therapeutic protein expression. An individual mRNA has a cap, 5′ and 3′ untranslated regions (UTRs), an open reading frame (ORF), and a polyadenylated (poly(A)) tail. There have been advancements in the design of each of these components. Most notable of these are: i) improved 5′ cap analogs that enhance translational capacity, but more importantly, the capping efficiency from 70% to 95%. ii) the poly(A) tail length optimization has proven critical for balancing the synthetic
Read more